Institution identification

PURI

https://redirect.ema.europa.eu/resource/19024

Institution ID

19024

Institution full name and acronym

Gilead Sciences

Type of institution

Pharmaceutical company

Institution website

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Cross-Sectional Post-Authorization Safety Study to Assess Healthcare Provider Awareness of Risks Associated with Zydelig® in the European Union
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
A Multi-center, Longitudinal, Clinical Real-World Study to Evaluate Mortality and Clinical Outcomes in Hospitalized Adults with COVID-19 Infection in the United States
A Multi-country, Non-interventional, Retrospective Drug Utilization Study in Haematological Malignancy Patients Treated for Probable or Proven Invasive Aspergillosis (AmBiVor)
A Multicenter, Multi-countiy Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19
A Multinational Observational Registry Collecting Data on the Profile of Patients with Chronic Hepatitis D Virus Infection Receiving Treatment with Bulevirtide (MYR-Reg-02)
A Prospective cohort study on the use of Sofosbuvir-based regimens in HCV-infected patients in clinical practice in France (HELIOS)
A Prospective, Longitudinal, Observational Registry of Truvada for HIV -1 Pre-Exposure Prophylaxis (PrEP) of Adults and Adolescents in Europe
A Prospective, Observational Drug Utilization Study of Cobicistat in Adults with HIV-1 Infection (GS-US-216-1230)
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada for Pre-Exposure Prophylaxis (PrEP)
A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir-boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR ≥ 70 mL/min
A Retrospective Observational Cohort Study to Evaluate the Effectiveness of Azacitidine Monotherapy in Treatment-naive Patients With Intermediate, High, and Very High-risk Myelodysplastic Syndrome
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study
Dose Optimization Study of Idelalisib in Follicular Lymphoma
GS-EU-276-4027: A Cross Sectional Post Authorization Safety Study to Assess Healthcare Provider’s Level of Awareness of Risk Minimisation Materials for Truvada® for Pre Exposure Prophylaxis in the European Union
GS-EU-337-1820 - An Observational Drug Utilization Study of Ledipasvir/Sofosbuvir and Tenofovir Disoproxil Fumarate + Pharmacokinetic Enhancer Co-Administration in Adults Co-Infected with Chronic Hepatitis C and HIV-1 Infections (HAVEN co-infection study)
Long-term, Non-interventional Study of Recipients of Tecartus for Treatment of Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Long-term, Non-interventional Study of Recipients of Yescarta® for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Follicular Lymphoma
Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF) (BIC-STaR)
Multicenter, Non-Interventional, Retrospective, Matched Cohort Study of Patients Monoinfected with Chronic Hepatitis B and with Moderate or Severe Renal Impairment Treated with Viread® or Baraclude® (ReCoRd)
Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Emtricitabine/Tenofovir alafenamide (F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in Germany (TAFNES)
Non-interventional retrospective study evaluating the real-life idelalisib use in the population enrolled in the French cohort Temporary Authorization for Use (ATUc) in Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) (REALIST)
Non-interventional study to assess the safety profile of idelalisib in patients with refractory follicular lymphoma (FL)
Observational, Cross-Sectional Post-Authorisation Safety Study to Assess Healthcare Provider Awareness of Risks Related to Sofosbuvir and Ledipasvir/Sofosbuvir (EU HVN SOF Survey Study)
Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe (Viread HBV PASS)
Prospective non-interventional post authorization safety study (PASS) of idelalisib in Germany
Prospective Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in France (TARANIS)
Quantitative Testing of Healthcare Provider Knowledge about YESCARTA® (axicabtagene ciloleucel) Risk Minimisation Measures
Real-life study of single tablet regimen (STR) and multi tablet regimen (MTR) usage in Germany on persistency of initial therapy - STRingent
Tecartus Survey: Quantitative Testing of Health Care Professional Knowledge About Tecartus® Risk Minimisation Measures
The Evaluation of Tenofovir Alafenamide Containing Regimens vs. Tenofovir Disoproxil Fumarate Containing Regimens on Renal Outcomes for Prevention, and Treatment of HIV and/or HBV Treatment: a Systematic Literature Review and Meta-analysis
VIR-Life: Prospective assessment of the real-life treatment outcomes of six years of Viread® in CHB following-up on the German Multicenter Non-Interventional Study GEMINIS
Viread Observational, Cross -Sectional Drug Utilisation Study in Children and Adolescents with Chronic Hepatitis B (Viread HBV DUS)